CLARITY PHARMACEUTICALS LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Phase 3

Recruiting

Conditions: Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: 64Cu-SAR-bisPSMA

First Posted Date: 2023-09-28

Last Posted Date: 2024-12-17

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 383

Registration Number: NCT06056830

Locations: 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇺🇸
Mayo Clinic- Phoenix, Phoenix, Arizona, United States
🇺🇸
Greater Los Angeles VA Medical Center, Los Angeles, California, United States

and more 18 locations

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

Phase 1

Recruiting

Conditions: Castration-Resistant
Prostatic Neoplasms

Interventions: Drug: 64Cu-SAR-BBN
Drug: 67Cu-SAR-BBN

First Posted Date: 2022-12-01

Last Posted Date: 2024-08-29

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 38

Registration Number: NCT05633160

Locations: 🇺🇸
Biogenix Molecular, Miami, Florida, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
XCancer Omaha LLC, Omaha, Nebraska, United States

and more 3 locations

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

Phase 2

Completed

Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate

Interventions: Drug: 64Cu-SAR-BBN

First Posted Date: 2022-06-07

Last Posted Date: 2024-06-14

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 53

Registration Number: NCT05407311

Locations: 🇺🇸
Bamf Health, Inc, Grand Rapids, Michigan, United States
🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸
Biogenix Molecular, Miami, Florida, United States

and more 5 locations

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Phase 1

Completed

Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate

Interventions: Drug: 64Cu-SAR-bisPSMA

First Posted Date: 2022-02-21

Last Posted Date: 2024-10-01

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 52

Registration Number: NCT05249127

Locations: 🇺🇸
GU Research Network, Omaha, Nebraska, United States
🇺🇸
New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
Tower Urology, Los Angeles, California, United States

and more 2 locations

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Phase 1

Recruiting

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: 64Cu-SAR-bisPSMA
Drug: 67Cu-SAR-bisPSMA

First Posted Date: 2021-05-03

Last Posted Date: 2024-03-27

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 44

Registration Number: NCT04868604

Locations: 🇺🇸
Weill Cornell Medicine at New York-Presbyterian, New York, New York, United States
🇺🇸
GU Research Network, Omaha, Nebraska, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

and more 2 locations

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: 64Cu-SAR-bisPSMA

First Posted Date: 2021-04-09

Last Posted Date: 2023-01-17

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 30

Registration Number: NCT04839367

Locations: 🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia
🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
GenesisCare CTA, SJOG Medical Clinic, Murdoch, Western Australia, Australia

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Early Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: 64Cu-SARTATE

First Posted Date: 2020-06-22

Last Posted Date: 2020-06-22

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 10

Registration Number: NCT04440956

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Tumors

Interventions: Drug: 64Cu-SARTATE

First Posted Date: 2020-06-18

Last Posted Date: 2024-05-14

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 63

Registration Number: NCT04438304

Locations: 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia

and more 1 locations

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Phase 1

Recruiting

Conditions: Neuroblastoma
Refractory Neuroblastoma
Relapsed Neuroblastoma

Interventions: Drug: 67Cu-SARTATE
Drug: 64Cu-SARTATE

First Posted Date: 2019-07-17

Last Posted Date: 2024-07-08

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 34

Registration Number: NCT04023331

Locations: 🇺🇸
University of Texas Southwestern Medical Centre, Dallas, Texas, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 5 locations

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

Phase 1

Completed

Conditions: Meningioma

Interventions: Drug: Cu-64 SARTATE and Cu-67 SARTATE

First Posted Date: 2019-05-03

Last Posted Date: 2020-04-20

Lead Sponsor: Clarity Pharmaceuticals Ltd

Target Recruit Count: 5

Registration Number: NCT03936426

Locations: 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy